EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Venetoclax combined with cladribine, idarubicin, cytarabine ( CLIA ‐ VEN ) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

Benjamin J Lee iD, Shawn P Griffin iD, Jean Doh, Anthony Quach, Yujiao Sun, Piyatida Chumnumsiriwath, Stefan O Ciurea, Jorge Ramos-Perez, Polina Bellman, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Benjamin J Lee und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive remission–induction therapy. In this retrospective study, outcomes of newly diagnosed adult AML patients who were consecutively treated with CLIA‐VEN ( n = 20; 2023–2025) were compared to a historical cohort that received 7 + 3 ( n = 42; 2016–2023). The median interquartile range [IQR] age was 54 [42–63] years, 54% were male and 58% had European LeukemiaNet (ELN) 2022 adverse‐risk disease. CLIA‐VEN was associated with a higher cumulative incidence of composite CR (CCR) (90% vs. 54.8%; p = 0.002) and minimal residual disease (MRD)‐negative CCR (93.8% vs. 40.9%; p < 0.001) at 28 days. Any grade ≥ 2 end‐organ toxicity (45% vs. 59.5%; p = 0.28) and early mortality (0% vs. 16.7%; p = 0.09) were not increased with CLIA‐VEN. Utilizing propensity score guided inverse probability treatment weighting to balance baseline demographics, receipt of CLIA‐VEN was associated with improved overall survival ( p = 0.002). Acknowledging the limitations of a retrospective single‐centre study, our data suggest that CLIA‐VEN has higher efficacy without increasing toxicity and the potential to prolong survival compared to the current standard of care in de novo AML patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedFemaleCytarabineIdarubicinAdultCladribineRetrospective StudiesRemission InductionBridged Bicyclo Compounds, HeterocyclicSulfonamidesInduction Chemotherapy

Stichwörter der Autor:innen

CLIAMRDacute myeloid leukaemiavenetoclax‘7 + 3’

Substanzen

CytarabineIdarubicinvenetoclaxCladribineBridged Bicyclo Compounds, HeterocyclicSulfonamides

Autor:innen und Institutionen

  • Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.
  • Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, California, USA.
  • Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Department of Medicine, Division of Hematology and Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange,…
  • Department of Medicine, Division of Hematology, Faculty of Medicine Naresuan Hospital, Naresuan University, Phitsanulok, Thailand.
  • Department of Medicine, Division of Hematology and Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.

ORCID-Profile: Benjamin J Lee, Shawn P Griffin

Zitieren

APA

Lee, B. J., Griffin, S. P., Doh, J., Quach, A., Sun, Y., Chumnumsiriwath, P., Ciurea, S. O., Ramos-Perez, J., Bellman, P., Jeyakumar, D., Kongtim, P., & Naqvi, K. (2026). Venetoclax combined with cladribine, idarubicin, cytarabine ( CLIA ‐ VEN ) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70253

Vancouver

Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Chumnumsiriwath P, et al. Venetoclax combined with cladribine, idarubicin, cytarabine ( CLIA ‐ VEN ) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia. British Journal of Haematology. 2026. doi:10.1111/bjh.70253

BibTeX
@article{Lee2026,
  author = {Lee, Benjamin J and Griffin, Shawn P and Doh, Jean and Quach, Anthony and Sun, Yujiao and Chumnumsiriwath, Piyatida and Ciurea, Stefan O and Ramos-Perez, Jorge and Bellman, Polina and Jeyakumar, Deepa and Kongtim, Piyanuch and Naqvi, Kiran},
  title = {Venetoclax combined with cladribine, idarubicin, cytarabine ( CLIA ‐ VEN ) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70253}
}
Kostenlos starten →